(1155) Identifying Markers for Gestational Diabetes Using Continuous Glucose Monitoring

This single-institution pilot prospective observational study includes pregnant individuals at 24-28 weeks’ with singleton gestation and 1-hour OGTT of 140-200mg/dl, without previous Type 1 or 2 Diabetes, PCOS, or recent metformin, insulin, or corticosteroid administration. Upon IRB approval, participants were screened through electronic medical records and recruited to wear Dexcom© G6 CGM in blinded mode for 7-10 days. Patients completed a 3-hour OGTT, determining GDM diagnosis. Pearson’s chi-square, independent samples t-test, and Mann-Whitney U tests were used as appropriate for analysis.

Results: CGM was worn by 22 participants, with 7 subsequently diagnosed with GDM. Metrics of CGM average glucose (124 vs. 111, p=0.011), time in range (82% vs. 90%, p=0.047), time above range (17% vs. 7%, p=0.021), and glucose management indicator (GMI), analogous to HbA1c, (6.3 vs. 6.0, p=0.009) significantly differed for those diagnosed with and without GDM, respectively (Table 1). Significant differences have not resulted in birth outcomes yet, with recruitment ongoing.

Conclusion: This study highlights CGM metrics that may be used as potential markers for patients at risk for GDM.